Insider Transactions in Q3 2021 at Oramed Pharmaceuticals Inc. (ORMP)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 16
2021
|
Kevin Rakin Director |
SELL
Open market or private sale
|
Direct |
21,100
-27.02%
|
$422,000
$20.99 P/Share
|
|
Sep 01
2021
|
David Silberman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Aug 31
2021
|
Nadav Kidron President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+11.78%
|
-
|
|
Aug 31
2021
|
Kevin Rakin Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+11.35%
|
-
|
|
Aug 31
2021
|
Joshua Hexter COO & CBO |
BUY
Grant, award, or other acquisition
|
Direct |
33,333
+24.39%
|
-
|
|
Aug 31
2021
|
Miriam Kidron Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,666
+32.0%
|
-
|
|
Aug 09
2021
|
Nadav Kidron President and CEO |
SELL
Open market or private sale
|
Direct |
220,000
-25.33%
|
$4,400,000
$20.11 P/Share
|
|
Aug 09
2021
|
Kevin Rakin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
26,093
-10.82%
|
$547,953
$21.09 P/Share
|
|
Aug 09
2021
|
Kevin Rakin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
79,136
+25.91%
|
$395,680
$5.74 P/Share
|
|
Aug 04
2021
|
Michael Rabinowitz Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|